Dogwood Therapeutics (NASDAQ:DWTX) Releases Quarterly Earnings Results, Misses Expectations By $0.21 EPS

Dogwood Therapeutics (NASDAQ:DWTX) posted its quarterly earnings data on Thursday. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.21), FiscalAI reports.

Dogwood Therapeutics Price Performance

Shares of Dogwood Therapeutics stock traded up $0.05 during trading hours on Thursday, hitting $1.97. The company’s stock had a trading volume of 17,962 shares, compared to its average volume of 76,775. The company has a market capitalization of $66.28 million, a PE ratio of -0.19 and a beta of 1.71. The stock has a 50 day moving average of $1.55 and a 200 day moving average of $2.05. Dogwood Therapeutics has a 12 month low of $1.28 and a 12 month high of $9.50.

Hedge Funds Weigh In On Dogwood Therapeutics

A hedge fund recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP bought a new position in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 9.05% of the company’s stock.

Wall Street Analysts Forecast Growth

DWTX has been the topic of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Dogwood Therapeutics in a report on Tuesday, May 19th. Weiss Ratings reissued a “sell (e+)” rating on shares of Dogwood Therapeutics in a research note on Friday, July 24th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $12.00.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.